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ABSTRACT
The iDISCO (immunolabeling-enabled three-dimensional imaging of solvent-
cleared organs) method is a quick, inexpensive, and easily adaptable tissue staining and 
clearing procedure that allows neuroscientists to study a protein of interest in a whole, 
unaltered tissue sample. While the iDISCO method was initially tested and validated for 
mice embryos and brains, the current experiment sought to adapt the method for use in 
the rat using HIV-1 transgenic (Tg) rat brain tissue. Antibodies for tyrosine hydroxylase 
and Iba-1 were validated in the HIV-1 Tg rat and in F344/N control rats using iDISCO. 
Confocal images were taken of tyrosine hydroxylase positive neurons in the substantia 
nigra area of male and female HIV-1 Tg and F344/N control rats. The HIV-1 Tg female 
rat was determined to have the most positive TH staining, followed by the control male, 
HIV-1 Tg male, and control female. Viewing the brain as a whole system rather than a 
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1.1 TISSUE CLEARING 
Immunohistochemical (IHC) staining is a common procedure used to identify a 
target protein in a tissue sample. First implemented in the mid-1900s, and used 
continuously since, IHC uses antigen specific antibodies to mark proteins of interest 
(Coons et al., 1941; Ramos-Vara, 2005). Most IHC procedures follow a similar 
workflow. First, a tissue sample is fixed to preserve the tissue’s morphology (Grizzle, 
2009). After fixation, samples can easily be cut into thin sections using a vibratome, 
cryostat, or brain matrix. Most traditional IHC procedures call for a tissue width of 
between 10-100 µm (West, 2012). Tissue samples are then blocked for endogenous 
materials present in the sample. Peroxidase blocking prevents blood cells from interfering 
with later imaging, and serum blocking of endogenous antibodies is essential to prevent 
cross-reactivity with the secondary antibody. A primary antibody corresponding to the 
protein of interest is used, followed by a secondary antibody corresponding to the animal 
of origin of the primary antibody. The secondary antibody either fluoresces when in the 
presence of a specific wavelength of light or is compatible for use with a permanent 
dyeing protocol, such as the avidin-biotin complex method (Ramos-Vara & Miller, 




Traditional IHC protocol are generally uncomplicated, inexpensive, versatile, and 
are compatible with the powerful statistical procedure of stereology (West, 2012). The 
aim of most IHC experiments is to determine localization or quantification of a protein of 
interest. However, there are limitations to conventional free-floating or slide-based IHC 
that can make analysis using stereology difficult.  
A tissue sample must meet strict criteria to be reliably assessed using stereology 
(West, 2012). First, conventional free-floating or slide-based IHC procedures involve 
dehydration steps and thus, tissues that start out appropriately thick may become too thin 
to be used in certain stereological probes. For tissue that is not homogenous, like the 
brain, dehydration-induced shrinkage of the sample may occur unevenly (Larsson, 1993). 
Second, traditional IHC protocols involve cutting the tissue samples into very thin (10-
100 µm) slices, which can cause further loss of cells, structures, or proteins of interest. 
Because of this loss, the top and bottom of tissue samples are usually neglected in 
stereology, and thus, tissue is wasted (West, 2012). Third, important biological structures 
must be cut into many pieces to be compatible with traditional IHC protocol. Structures 
in pieces can no longer easily be analyzed as a whole, or as a component of a larger 
system. Finally, slide-based or free-floating protocols do not usually allow for deep 
penetration of the antibodies. Even if an antibody were able to penetrate a thicker sample, 
the sample would likely be too optically opaque to allow for the light penetration 
necessary for visualization on a microscope (Ariel, 2017). 
 Tissue clearing offers a solution to the aforementioned limitations of traditional 
IHC protocol. A sample that is transparent minimizes the scattering and absorption of 
light, which provides cellular level optical access to tissues that are intact (Rocha et al., 
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2019; Richardson & Lichtman, 2015). Tissue clearing techniques turn a tissue transparent 
through delipidation, decolorization, and decalcification with the administration of 
solvents. Once the refractive index of the tissue sample matches the refractive index of 
the chosen imaging medium, the sample will appear completely transparent and can be 
properly imaged (Ueda et al., 2020).  
Several tissue clearing techniques have been validated for use in the brain: 
hydrogel, hydrophilic, and hydrophobic. Hydrogel based techniques, such as CLARITY, 
secure biomolecules in the tissue by linking them to acryl-based hydrogels, which 
prevents structural damage and loss of proteins (Chung et al., 2013). However, hydrogel 
techniques utilize harsh chemicals that have the potential to damage more fragile tissues 
or antibodies, and denser tissue samples may not be compatible with some hydrogel 
protocol. Certain hydrogel techniques may also require expensive equipment or lead to 
tissue expansion. Hydrophilic techniques, like CUBIC and FocusClear, preserve 3D 
structure through the formation of hydrogen bonds within the tissue (Susaki, et al., 2014). 
Tissue expansion can also occur in certain hydrophilic protocol. The clearing ability of 
hydrogel and hydrophilic techniques often does not match that of hydrophobic methods, 
which is crucial for denser and thicker tissues (Ueda et al., 2020). 
Immunolabeling-enabled three-dimensional imaging of solvent-cleared organs 
(iDISCO) is a hydrophobic clearing technique that improves upon previous hydrophobic 
techniques by eliminating the shrinkage that can occur (Renier et al., 2014). The iDISCO 
procedure removes water from the tissue in the initial dehydration step, thus reducing 
light scatter. Tissue is permeabilized during pretreatment to allow deep antibody 
penetration. Tissue that has undergone the iDISCO protocol is able to be handled easily 
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and can be imaged several times. If properly stored, tissues can still provide images for 
up to a year after initial processing. A hydrophobic technique such as iDISCO is 
relatively fast, does not require special equipment, and produces a sample that is easy to 
handle and store.  
Originally, the iDISCO tissue clearing technique was described by Renier et al. 
(2014), who extended the utility of the 3DISCO procedure to include mice embryos and 
denser, adult organs of mice. The iDISCO technique has been implemented many times 
in mice, to great success (Renier et al, 2016; Silvestri et al., 2016). To date, however, the 
technique’s full clearing ability has not been as well established in rats (Jing et al., 2018; 
Qi et al., 2019). Validation in the rat brain serves as an important advancement, as rats 
are used in approximately 50% of neuroscience publications and offer many advantages 
over mice due to their larger brain size and behavioral differences (Ellenbroek & Youn, 
2016).  
The first goal of the present experiment was to therefore demonstrate the full 
clearing ability of iDISCO in a commonly used species of laboratory rat, the F344/N 
Fischer rat. Because of their utility in neuroscience research, transgenic models of 
infectious diseases have been created in the species, such as the HIV-1 transgenic (Tg) 
rat. 
1.2 HIV 
The HIV-1 Tg rat was created on the F344/N background and provides 
researchers with a non-infectious animal model for HIV-1 (Reid et al., 2001). The HIV-1 
provirus present in the transgenic rats has a functional deletion of two (gag and pol) of 
the three (gag, pol, and env) structural genes necessary for production of viral particles. 
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Despite these deletions, the genes of the provirus encoding for regulatory and accessory 
proteins, such as tat, remain functional. The HIV-1 Tg rat is a non-infectious model for 
HIV-1 induced viral protein exposure on brain function and overt behavior, which results 
in a model that is useful for studying the effect of viral proteins in the absence of active 
infection (Bertrand et al., 2018; Reid et al. 2001; Vigorito et al. 2015; McLaurin et al., 
2018). 
There are an estimated 37.9 million adults living with HIV, with 1.7 million new 
HIV infections occurring in 2018 alone (UNAIDS, 2019). To control the infection, 
individuals with the virus are often prescribed combination antiretroviral therapy (cART), 
a combination of fusion inhibitors, nucleotide and non-nucleotide reverse transcriptase 
inhibitors, integrase inhibitors, CCR5 antagonists, and protease inhibitors meant to 
suppress viral replication and block new infection (Bertrand et al., 2015; Sengupta & 
Siliciano, 2018). cART suppresses the virus’s ability to replicate, which reduces the 
amount of circulating virus that is immune to treatment (Sengupta & Siliciano, 2018; 
Smyth et al., 2012). HIV-1 can enter a state of latency in some infected cells (Sengupta & 
Siliciano, 2018). Despite the suppression of replication from cART, latent HIV infection 
is still able to release HIV-1 neurotoxic proteins through astrocytes and microglia 
(Bertrand et al., 2015; Bertrand et al., 2014). Even transient exposure to these proteins 
may be enough to trigger a cascade of cellular events, such as apoptosis or inflammatory 
responses, that could lead to dendritic or synaptic loss (Aksenova et al., 2006; Bertrand et 
al., 2014).  
Dysregulation of the dopaminergic system associated with HIV-1 has been well 
established in both human, clinical populations (Silvers et al., 2006; Gelman et al., 2006; 
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Kumar et al., 2011) and transgenic animal models (Lee et al., 2014; Javadi-Paydar et al., 
2017; Bertrand et al., 2018). HIV-1 viral proteins Tat and gp120 have been theorized to 
directly affect the dopaminergic system, leading to behavioral and motivational 
alterations (Bennet et al., 1995; Fitting et al., 2015; Moran et al., 2012; Bertrand et al., 
2018). Previous studies in the HIV-1 Tg rat have shown that dopaminergic impairment is 
greater in HIV-1 Tg animals when compared to controls; sex differences are also present, 
with HIV-1 Tg female rats being the most impaired group in both chemical and 
behavioral measures (Denton et al., 2019; McLaurin et al., 2017).  
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the primary pathway of 
dopamine synthesis, and its detection is often used to draw conclusions about an 
organism’s dopaminergic system. Decreased TH immunostaining in the striatum and 
substantia nigra areas indicate an enzymatic deficit in dopaminergic projections (Daubner 
et al., 2011). TH has previously been studied in the HIV-1 Tg rat using traditional IHC 
methodology (Goulding et al., 2019; Moran et al., 2012). At 8 months, male HIV-1 Tg 
rats were found to have significantly less TH+ staining when compared to controls; this 
same effect was not seen in younger (2-5 month old) rats (Goulding et al., 2019). In the 
present study, TH is used as an enzymatic marker for dopamine synthesis. It is 
hypothesized that HIV-1 Tg rats will show more TH impairment than controls, with HIV-
1 Tg females showing the greatest impairment. The TH antibody used is rabbit 
polyclonal, and labels 62kDa, which corresponds to tyrosine hydroxylase (AB152, 
Millipore Sigma). 
Microglia are a type of glial cell responsible for responding to cellular level 
threats that occur in the brain (Frank et al., 2019; Crotti et al., 2016). “Resting” microglia 
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sample the environment to look for threats with long, branching processes, while 
“activated” microglia will seek and destroy bacteria or foreign cells (Nimmerjahn et al., 
2005). Microglia will activate in response to various stressors in the brain, such as 
physical trauma, seizure, or infections such as HIV-1 (Frank et al., 2019; Goulding et al., 
2019; Rowson et al., 2016; Vera et al., 2016; Liu et al., 2018). Activation of microglia 
causes inflammation, which can induce a variety of behavioral, endocrine, and neural 
responses in multiple brain regions (Banks et al., 2015; Guillemin et al., 2004). Ionized 
calcium-binding adapter molecule 1 (Iba1) is a protein present in microglia that increases 
with activation (Ohsawa et al., 2004). Due to the interaction between the HIV-1 virus and 
microglia, and the effects of inflammation on the brain, microglia are an important target 
of study (Hauser & Knapp, 2015). The present study seeks to confirm the compatibility 
of an Iba1 antibody with the iDISCO clearing method for use in the HIV-1 Tg rat. The 
Iba1 antibody used is rabbit polyclonal, and was raised against a synthetic peptide 
corresponding to the Iba1 carboxy-terminal sequence (019-19741, FUJIFILM Wako). 
The present experiment has three objectives. The first, and main, objective is to 
establish the validity of the iDISCO tissue clearing technique in F344/N and HIV-1 Tg 
rat brain tissue. The second objective is to validate two antibodies (TH and Iba1) for use 
in rat brain tissue. The third objective is to investigate the levels of TH+ staining in male 
and female HIV-1 Tg and F344/N control rats to more clearly understand the impact of 
HIV-1 associated viral protein exposure on dopamine production throughout the nigra-
striatal and mesocorticolimbic dopamine systems. Using the iDISCO tissue clearing 
technique as a guide, TH and Iba1 antibodies were administered to male and female 
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F344/N control and HIV-1 Tg rat brains, with TH serving as a marker for dopamine 

























MATERIALS AND METHODS 
2.1 ETHICS STATEMENT 
The present research was conducted in accordance with the recommendations 
listed in the Guide for the Care and Use of Laboratory Animals from the National 
Institutes of Health. All rats used were housed in an AAALAC-accredited facility, with 
all procedures approved by the University of South Carolina Institutional Animal Care 
and Use Committee (IACUC). 
2.2 SUBJECTS 
 One HIV-1 Tg female, one HIV-1 Tg male, one F344/N control female, and one 
F344/N control male were used for the present study. Dames to the subjects were 
obtained from Envigo (Indianapolis, IN). All rats were housed under conditions targeted 
to 21° ± 2 °C, 50% ±10% relative humidity with a 12 hour light-dark cycle. Subjects 
were housed with their littermates until the day of weaning. 
2.3 SAMPLE PREPARATION 
Ingredients for all solutions can be found in Appendix A. Supplier information for 
each chemical can be found in Appendix B. On the day of weaning (approximately 
postnatal day 21 to 24), a rat from a litter meeting proper transgene and sex criteria was 
selected for sacrifice. Rats were deeply anesthetized using sevoflurane. The rat was 
considered sufficiently anesthetized when it failed to respond to toe and tail pinch. In a 
fume hood, rats were laid supinely, and a lateral incision was made through the 
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abdominal wall beneath the rib cage to prepare for perfusion. A cut was made up through 
the bottom of the rib cage to the collarbone, cutting the diaphragm along the length of the 
rib cage. The left ventricle was pierced with a 23-gauge needle attached to a perfusion 
pump. After cutting open the right atrium, the perfusion began. Approximately 75mL of 
room temperature (RT) 100mM (1X) phosphate buffered saline (PBS) was used to flush 
the vasculature. The transcardial perfusion was continued with approximately 100mL of 
4% paraformaldehyde (PFA) buffered in 1X PBS. Once the rat was fully perfused, the 
brain was removed from the skull. Meninges were removed. Each brain was sliced 
sagittally using a razor blade into sections approximately 3mm in width. Each section 
was fixed in 4% PFA in 1X PBS in a sealed, 5mL plastic tube overnight at 4° C on a 
shaker. All steps were performed in fully filled, closed tubes to avoid oxidation of the 
samples. The next day, sections continued to fix at RT on a shaker for 1 additional hour. 
Sections were placed in a new 5mL tube and were washed 3 times with 1X PBS at RT for 
30 minutes. 
2.4 METHANOL PRETREATMENT 
 Samples were incubated in increasing concentrations of methanol for 1 hour per 
concentration at RT. The concentrations used were 20% methanol/80% deionized water, 
40% methanol, 60% methanol, 80% methanol, and 100% methanol twice. Each sample 
was then chilled in fresh 100% methanol at 4° C for approximately 10 minutes. Samples 
were then incubated overnight in a 66% dicholoromethane/33% methanol solution at RT 
with shaking. Each sample was washed with methanol at RT for 30 minutes, twice. 
Samples were then chilled in 100% methanol at 4° C for approximately 10 minutes. 
Samples were bleached in chilled, freshly prepared 5% hydrogen peroxide/95% methanol 
 
11 
overnight at 4° C. Samples were then rehydrated in decreasing concentrations of 
methanol for 1 hour per concentration at RT. The concentration order used was 80% 
methanol/20% deionized water, 60% methanol, 40% methanol, 20% methanol, followed 
by a 1 hour incubation of 1X PBS. Samples were washed in PTx.2 for 1 hour at RT, 
twice. 
2.5 IMMUNOLABELING 
 Samples were incubated in permeabilizing solution for 2 days at 37°C in a closed, 
incubator water bath. After removal from the permeabilizing solution, samples were 
incubated in blocking solution for 2 days at 37°C in a closed, incubator water bath. After 
2 days, one hemisphere from each animal was incubated with the tyrosine hydroxylase 
(TH) primary antibody at a concentration of 1:100 (AB152, Millipore Sigma) in 92% 
PTwH/5% DMSO/3% goat serum for 7 days at 37°C in a closed, incubator water bath. 
The other hemisphere was incubated with the Iba1 primary antibody (019-19741, 
FUJIFILM Wako) at a concentration of 1:200 in the same solution and conditions. After 
7 days, samples were washed in PTwH 5 times at 1 hour per wash, and then stored in 
PTwH at RT overnight. The next day, samples were incubated in Alexa Fluor Plus 647 
(A32733, Invitrogen) secondary antibody in 97% PTwH/3% goat serum for 7 days at 
37°C in a closed, incubator water bath. Goat serum was used because it corresponded 
with the secondary antibody chosen for labelling. Samples were washed in PTwH 5 times 
at 1 hour per wash, and then stored in PTwH at RT overnight. 
2.6 CLEARING 
 Samples were incubated in increasing concentrations of methanol for 1 hour per 
concentration at RT. The concentrations used were 20% methanol/80% deionized water, 
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40% methanol, 60% methanol, 80% methanol, and 100% methanol. The samples were 
then incubated overnight in fresh 100% methanol at RT. After this, samples were 
incubated in 66% DCM/33% methanol for 3 hours, with shaking, at RT. Samples were 
then placed in DBE and left in a dark place at RT until ready for mounting. Samples were 
mounted after they were clear.  
2.7 MOUNTING 
 3D printed chambers were ordered using the 3D models found on the idisco.info 
website. Chambers were printed using Visijet M3 Crystal resin, as it is will not degrade 
in the presence of DBE. Chambers with a depth of 3mm were used. Chambers were 
secured to microscope slides using Kwik-sil epoxy (VWR), which cures in the presence 
of DBE. This epoxy also does not form a permanent bond to the chamber, so samples are 
able to be remounted and reimaged. Samples were placed in the space within the 
chamber, and the chamber was filled with DBE. A 0.17 mm coverslip was placed over 
the chamber, and light pressure was applied to the slide to flatten the sample and form a 
seal with the chamber. While still applying pressure, the edges of the coverslip were 
sealed with Kwik-sil epoxy. Pressure was applied for 5 minutes until the epoxy cured. 
After curing, the chamber was rotated to allow air bubbles to escape from the filling inlet. 
Additional DBE was added into the chamber via a syringe to ensure that the sample was 
not exposed to air. The filling inlet was sealed with epoxy. 
2.8 IMAGING 
 Images were obtained using a Nikon TE-2000E confocal microscope (Nikon, 
Tokyo, Japan) running Nikon’s EZ-C1 software (version 3.81b). Tyrosine hydroxylase 
excitation was achieved utilizing a HeNe laser set to emit at 632 nm. The detector was set 
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to 650 nm. Images were obtained at 4x and 10x magnification, using the medium and 
large pinhole sizes provided by the EZ-C1 software. The 650LP gain for all images was 
set to 7.50 B. The substantia nigra, nucleus accumbens, prefrontal cortex, and ventral 
tegmental areas were identified and imaged in each rat when possible. Approximately 20 
images were obtained per animal.  
2.9 ANALYSIS  
Out of the approximately 20 images obtained for each animal, the 4 images per 
animal which displayed the most positive fluorescence were chosen. Each animal was 
ranked from greatest to least TH expression. The ranking was first established by the 
primary researcher, but to avoid potential bias, three other researchers who were blind to 
condition were given criteria for positive staining and were also allowed to rank the 
overall TH expression of each animal. Four representative images were obtained for each 
animal used. Figure 2.1 shows a representative confocal image for TH in the substantia 
nigra region shown to all other raters. Raters blind to condition were shown this image, 
along with the description that marker “A” represents dense, positive staining, marker 
“B” represents sparse positive staining, and marker “C” represents tissue that is not 






Figure 2.1: A representative confocal image from the HIV-1 Tg female (4x 
magnification). “A” represents dense TH staining, “B” sparse TH staining, and 






F344/N and HIV-1 Tg rat brain tissues were able to be fully cleared by the present 
study’s adjusted tissue clearing protocol (Figure 3.1). Increasing the length of the 
antibody incubation time allowed the antibody to fully penetrate the thick tissue. 
Changing the blocking serum to correspond according to the primary antibody reduced 
background staining. There was no noticeable difference in clearing between HIV-1 Tg 
tissue and F344/N control tissue. 
TH and Iba1 staining were both compatible with the tissue clearing method used 
and had no noticeable detrimental interactions with the HIV-1 provirus. Figure 3.2 shows 
typical morphology of a TH positive neuron, with a large soma and several branching 
processes (Roostalu et al., 2019). Figure 3.3 shows Iba1 stained activated microglia, 
which have small cell bodies and shorter extending processes (Ransohoff & Cardona, 
2010). Because the expected cell morphology was observed, the antibodies were 
considered to be successful in staining and compatible with the protocol. 
Four representative images were chosen for each animal used. Blinded rankings 
were in 100% agreeance with the non-blinded ranking. The order of most to least TH+ 
staining was determined to be as follows: HIV-1 Tg female (Figure 3.4), F344/N control 














































The immunostaining findings from the present study partially supported the 
original hypothesis. HIV-1 Tg females were determined to have the most TH+ staining, 
followed by F344/N males, HIV-1 Tg males, and F344/N females. Previous research has 
shown that TH staining in the substantia nigra is reduced in HIV-1 Tg male rats, with 
more TH loss seen over time (Webb et al., 2010; Goulding et al., 2019). This finding is 
also present in male-dominated studies of adult HIV-1 infected human brain tissue 
(Gelman et al., 2006). In the present study, this same effect was also seen, with the 
F344/N control male rat showing more TH positive staining when compared to the HIV-1 
Tg male. 
When compared to their male counterparts, HIV-1 Tg females present delayed 
task acquisition, less accurate signal detection, decreased dopamine release, impaired 
temporal processing, and decreased locomotor activity (McLaurin et al., 2017; Denton et 
al., 2019). Estrogen and phytoestrogens have been shown to prevent neuronal damage 
caused by Tat, reverse F-actin loss, and reduce HIV-1 associated motor and cognitive 
dysfunction (Adams et al. 2010; Bertrand et al. 2015; Wallace et al. 2006). Sex 
differences have also been observed in human clinical populations, where HIV-1 positive 
women have been shown to have higher levels of neurocognitive impairment than HIV-1 
positive men (Royal et al., 2016; Sundermann et al., 2019). Based on this prior research, 
it was expected that the traditionally impaired HIV-1 Tg females would also have the 
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lowest overall TH levels. This was not the case, as the HIV-1 Tg female was determined 
to have the most positive TH staining out of the four animals tested. The current data 
suggest the presence of a sex by genotype interaction in relation to TH. 
TH is traditionally used as an indicator of dopamine production. However, it is 
not entirely correct to make the assumption that more TH always indicates more 
dopamine production. TH is the rate-limiting enzyme that catalyzes the hydroxylation of 
tyrosine to L-DOPA, which can then be converted to dopamine using aromatic amino 
acid decarboxylase (Flatmark, 2000). TH is activated when the amount of 
neurotransmitter required increases at a catecholaminergic synapse, and activation is 
sustained until the requirement is lessened. TH is inactivated via feedback inhibition from 
the catecholamine neurotransmitters it helps create (Daubner et al., 2011). Previous 
research has shown that TH concentration and activation can even be increased following 
the destruction of catecholaminergic terminals, as if to compensate for the loss (Zigmond 
et al., 1984; Acheson et al., 1981). The increased TH levels seen in the female HIV-1 rat 
of the present study are possibly part of the compensatory action of TH in response to 
lowered dopamine in the system (Iuvone, 1983). Metabolite level differences have been 
previously been observed in HIV-1 positive patients when compared to controls 
(Ghannoum et al., 2013). With this in mind, an important consideration is the role that the 
HIV-1 virus might have in affecting other chemicals in the chain of dopamine synthesis 
such as L-DOPA, DOPA decarboxylase, or phenylalanine hydroxylase. 
The present data have several severe limitations. Firstly, it cannot be ignored that 
each sex and genotype was represented by only one subject, which opens up the 
possibility that a non-representative subject happened to be randomly chosen. Thus, 
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while preliminary differences exist in this small sample size, a larger sample is necessary 
to confirm the present observed differences. The data presented here are observational in 
nature, and are not backed by any quantitative analysis. Quantitative analyses are limited 
by the tools currently available for the rat brain. Currently, investigative tools such as 
ClearMap exist to analyze cleared tissue of the mouse brain, but 3D rat brain atlases are 
still in development (Renier et al., 2016; Branch et al., 2019).  
For the present study, rats were processed on the day of weaning (approximately 
day 21 of life). While it is not proper to make a direct comparison between rat age and 
the corresponding age of a human, a rat of weaning age is closer developmentally to a 
pre-pubescent human than to an adult (Sengupta, 2013). Rats do not reach sexual 
maturity until approximately 7 weeks of age, which means that female rats at weaning 
have not yet established their estrous cycles (Blunn, 1939). It is possible that female HIV-
1 Tg rats have more TH than control females before sexual maturity, but more research 
would be needed to consider this possibility. As women account for roughly half of 
human HIV-1 cases, and sex differences are consistently observed in HIV-1 Tg rats, sex 
effects and interactions should continue to be investigated down to the molecular level 
(UNAIDS, 2019). 
The tissue clearing results from the present study exhibited that the hydrophobic 
iDISCO clearing method is viable in large sections of both F344/N control and HIV-1 Tg 
rat brain tissue. The present protocol differs in a few important ways from the original by 
Renier, et al. (2014). Firstly, overall reduction of background staining was achieved by 
specifying the blocking serum used in the blocking, primary, and secondary antibody 
steps. Clearer images, reduced background signal, and more accurate staining was 
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achieved by using the serum corresponding to the secondary antibody (in this case, goat), 
instead of the donkey serum used in the original iDISCO protocol. Incubation time across 
the protocol was increased to account for larger tissue size and differing tissue density, 
which allowed for complete antibody penetration. TH and Iba1 antibodies were both 
validated for use with this method and in F344/N control and HIV-1 Tg rat brain tissue. 
There are a few important considerations and limitations to the present tissue-
clearing protocol. Despite the desire to leave the brain tissue intact, cutting the tissue to a 
smaller size is necessary due to the current physical limitations of the iDISCO imaging 
chambers. Maximum tissue thickness is also limited by the physical limitations of the 
confocal microscope; chambers that exceed a certain vertical height will collide with the 
lenses of the confocal microscope, and extremely thick tissues may not be able to be 
properly focused. While tissue clearing provides the advantage of imaging thicker tissue 






CONCLUSIONS AND FUTURE DIRECTIONS 
Overall, the iDISCO technique is an extremely versatile, easy to implement, and 
low cost procedure with a growing list of validated antibodies. The present study 
provides continued evidence that the iDISCO tissue clearing technique is viable in brain 
tissues of the rat, has no discernible detrimental interactions with HIV-1 viral proteins, 
and is compatible with TH and Iba1 antibodies. Now, new investigative research 
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  Table B.1: Supplier information and catalog numbers. 
Name of Material/Equipment Company Catalog Number 
DBE Sigma-Aldrich 108014-1KG 
DCM Sigma-Aldrich 270997-100mL 
DMSO Sigma-Aldrich 472301-1L 
Glycine Fisher Chemical G46-500 
Goat anti-rabbit Alexa Fluor Plus 647 Invitrogen A32733 
Goat serum Sigma Life Science G9023-10mL 
Heparin Acros Organics 41121-0010 
Iba1 primary antibody FUJIFILM Wako 019-19741 
Kwik-sil epoxy VWR MSPP-KWIK-SIL 
Methanol Sigma-Aldrich 34860-1l-R 
PBS Fisher Bioreagents BP2944-100 
Perfusion pump VWR 70730-062 
PFA Sigma-Aldrich 158127-3KG 
TritonX-100 Fisher Bioreagents BP151-500 
Tween-20 Fisher Bioreagents BP337-500 
Tyrosine hydroxylase primary antibody Millipore Sigma AB152 
 
